Monte Rosa Therapeutics
GLUE
70 hedge funds and large institutions have $329M invested in Monte Rosa Therapeutics in 2022 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 21 increasing their positions, 15 reducing their positions, and 3 closing their positions.
433% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 3
40% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 15
23% more funds holding
Funds holding: 57 → 70 (+13)
3.09% more ownership
Funds ownership: 83.09% → 86.18% (+3.1%)
12% less capital invested
Capital invested by funds: $375M → $329M (-$46.2M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$7.65M |
| 2 |
BlackRock
New York
|
+$1.45M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.4M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$1.16M |
| 5 |
O
OrbiMed
New York
|
+$1.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$13.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.86M |
| 3 |
Allianz Asset Management
Munich,
Germany
|
-$1.18M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$183K |
| 5 |
Morgan Stanley
New York
|
-$161K |
GLUE Hedge Fund Activity: Q3 2022 in Review
70 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Monte Rosa Therapeutics (GLUE) for Q3 2022, worth a combined $329M — down 12% from $375M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new GLUE positions and 3 closed out — a net gain of 13 holders — while 21 added to existing stakes and 15 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $7.65M. The largest seller was T. Rowe Price Associates, cutting an estimated $13.6M.
- 70 institutional investors held Monte Rosa Therapeutics (GLUE) as of Q3 2022, up from 57 in Q2 2022.
- Funds reported $329M of Monte Rosa Therapeutics stock for Q3 2022, down 12% quarter-over-quarter.
- 16 funds opened new Monte Rosa Therapeutics positions in Q3 2022 and 3 closed out, a net change of +13 holders.
- The largest Monte Rosa Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $7.65M added.
- The largest Monte Rosa Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $13.6M sold.
Based on aggregated 13F filings for Q3 2022.